MEDI4736-MM-005 (FUSION MM-005): A Phase 2, Multicenter, Single-Arm, Study to Determine the Efficacy for the Combination of Durvalumab (DURVA) Plus Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) That Have Progressed While on Current Treatment Regimen Containing Daratumumab
Latest Information Update: 29 Jul 2019
At a glance
- Drugs Daratumumab (Primary) ; Durvalumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms FUSION-MM-005
- Sponsors Celgene Corporation
- 22 Jul 2019 Results assessing a population-PK model of durvalumab using pooled data from four clinical trials of haematologic malignancies (NCT02775903, NCT02685826, NCT03000452, NCT02733042) and the model structure and covariate effects were compared with those in solid tumours published in the Clinical Pharmacokinetics
- 18 Sep 2018 Status changed to completed.
- 29 Jan 2018 Status changed from suspended to discontinued.